Clovis CEO Patrick Mahaffy (Getty)
March 31, 2022 02:07 PM EDT
Bioregnum
Pharma

Clo­vis On­col­o­gy her­alds a PARP vic­to­ry in front­line ovar­i­an can­cer — does any­one re­al­ly care much?

Ear­ly on Thurs­day, Clo­vis On­col­o­gy trum­pet­ed pos­i­tive Phase III da­ta for their PARP play­er Rubra­ca in front­line main­te­nance care of ovar­i­an can­cer, out­lin­ing a much …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times